Gal-3 levels were also analyzed with two-way factorial ANOVA in treatment naïve patients with or without a confirmed diagnosis of AML, grouped according to severe LAM (%FEV1 <80) and mild LAM (%FEV1 >80). This evidence concerns the gene LGALS3 and lymphangioleiomyomatosis.